This case-control study evaluates the association of nirsevimab with the prevention of respiratory syncytial virus (RSV) infection among at-risk infants after implementation of a universal immunization strategy in Chile.
JAMA Network Open published a clinical update in Research Highlights on 10 Apr 2026.
The item focuses on Nirsevimab in High-Risk Infants in an RSV Prevention Strategy.
Review the original article for the full source wording and details.